Jeffrey W. Moses

Jeffrey W. Moses

Auto-generated profile, based on publicly available information

Jeffrey W. Moses

St. Francis Hospital, Roslyn, NY (R. Shlofmitz, J.M.).

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2021 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
MZMingyou Zhang
Mingyou Zhang
MMMitsuaki Matsumura
Mitsuaki Matsumura
EUEisuke Usui
Eisuke Usui
MNMasahiko Noguchi
Masahiko Noguchi
TFTatsuhiro Fujimura
Tatsuhiro Fujimura
AMAkiko Maehara
Akiko Maehara
Background: Coronary calcification inhibits stent expansion. We sought to establish an intravascular ultrasound–derived calcium score to predict stent underexpansion. Methods: This is a retrospective observational study including de novo lesions that underwent intravascular ultrasound–guided stenting and had maximum superficial calcium angle >270°. Lesions with angiographic calcium not treated with atherectomy or scoring/cutting balloon before stent implantation were randomly divided into derivation and validation cohorts. The end point was stent expansion (minimum stent area/average of reference lumen area) at the maximum calcium site, and stent expansion 270° longer than 5 mm (regression coefficient, −13.0 [95% CI, −18.1 to −7.8], P <0.0001), (2) 360° of superficial calcium (regression coefficient, −14.2 [95% CI, −22.8 to −5.5], P =0.001), (3) calcified nodule (regression coefficient, −8.3 [95% CI, −14.3 to −2.2], P =0.007), and (4) vessel diameter <3.5 mm (regression coefficient, −9.4 [95% CI, −16.0 to −2.7], P =0.006). The calcium score (0-4) was significantly correlated with poor stent expansion (regression coefficient, −8.1 [95% CI, −10.5 to −5.7], P <0.0001) in the validation cohort as well as in the atherectomy cohort (regression coefficient, −4.8 [95% CI, −7.2 to −2.5], P <0.0001) with significant interaction between validation and atherectomy cohorts ( P interaction =0.02). In lesions without angiographic calcium, all calcium severity parameters were less than in the validation cohort, and stent underexpansion was observed in only 1.5% (1/67) of lesions. Conclusions: This intravascular ultrasound calcium score provides the interventionalists with a reliable tool to identify calcified stenoses at risk for stent underexpansion and requiring adjunctive calcium modification before stent implantation.

16 January 2024 in Journal of the American Heart Association
Verified
Journal Article
Open access
JSJayakumar Sreenivasan
Jayakumar Sreenivasan
RRRohin Reddy
Rohin Reddy
YJYasser Jamil
Yasser Jamil
AMAaqib Malik
Aaqib Malik
DCDaniel Chamie
Daniel Chamie
YAYousif Ahmad
Yousif Ahmad
Background: Despite the initial evidence supporting the utility of intravascular imaging to guide percutaneous coronary intervention (PCI), adoption remains low. Recent new trial data have become available. An updated study‐level meta‐analysis comparing intravascular imaging to angiography to guide PCI was performed. This study aimed to evaluate the clinical outcomes of intravascular imaging–guided PCI compared with angiography‐guided PCI. Methods and Results: A random‐effects meta‐analysis was performed on the basis of the intention‐to‐treat principle. The primary outcomes were major adverse cardiac events, cardiac death, and all‐cause death. Mixed‐effects meta‐regression was performed to investigate the impact of complex PCI on the primary outcomes. A total of 16 trials with 7814 patients were included. The weighted mean follow‐up duration was 28.8 months. Intravascular imaging led to a lower risk of major adverse cardiac events (relative risk [RR], 0.67 [95% CI, 0.55–0.82]; P <0.001), cardiac death (RR, 0.49 [95% CI, 0.34–0.71]; P <0.001), stent thrombosis (RR, 0.63 [95% CI, 0.40–0.99]; P =0.046), target‐lesion revascularization (RR, 0.67 [95% CI, 0.49–0.91]; P =0.01), and target‐vessel revascularization (RR, 0.60 [95% CI, 0.45–0.80]; P <0.001). In complex lesion subsets, the point estimate for imaging‐guided PCI compared with angiography‐guided PCI for all‐cause death was a RR of 0.75 (95% CI, 0.55–1.02; P =0.07). Conclusions: In patients undergoing PCI, intravascular imaging is associated with reductions in major adverse cardiac events, cardiac death, stent thrombosis, target‐lesion revascularization, and target‐vessel revascularization. The magnitude of benefit is large and consistent across all included studies. There may also be benefits in all‐cause death, particularly in complex lesion subsets. These results support the use of intravascular imaging as standard of care and updates of clinical guidelines.

17 May 2021 in European Heart Journal
Verified
Journal Article
Open access
PDF file
ALAlexandra J Lansky
Alexandra J Lansky
RMRajendra Makkar
Rajendra Makkar
TNTamim Nazif
Tamim Nazif
SMSteven Messé
Steven Messé
JFJohn Forrest
John Forrest
JMJeffrey Moses
Jeffrey Moses
The REFLECT I trial investigated the safety and effectiveness of the TriGuard™ HDH (TG) cerebral embolic deflection device in patients undergoing transcatheter aortic valve replacement (TAVR). This prospective, multicentre, single-blind, 2:1 randomized (TG vs. no TG) study aimed to enrol up to 375 patients, including up to 90 roll-in patients. The primary combined safety endpoint (VARC-2 defined early safety) at 30 days was compared with a performance goal. The primary efficacy endpoint was a hierarchical composite of (i) all-cause mortality or any stroke at 30 days, (ii) National Institutes of Health Stroke Scale (NIHSS) worsening at 2–5 days or Montreal Cognitive Assessment worsening at 30 days, and (iii) total volume of cerebral ischaemic lesions detected by diffusion-weighted magnetic resonance imaging at 2–5 days. Cumulative scores were compared between treatment groups using the Finkelstein–Schoenfeld method. A total of 258 of the planned, 375 patients (68.8%) were enrolled (54 roll-in and 204 randomized). The primary safety outcome was met compared with the performance goal (21.8% vs. 35%, P < 0.0001). The primary hierarchical efficacy endpoint was not met (mean efficacy score, higher is better: −5.3 ± 99.8 TG vs. 11.8 ± 96.4 control, P = 0.31). Covert central nervous system injury was numerically lower with TG both in-hospital (46.1% vs. 60.3%, P = 0.0698) and at 5 days (61.7 vs. 76.2%, P = 0.054) compared with controls. REFLECT I demonstrated that TG cerebral protection during TAVR was safe in comparison with historical TAVR data but did not meet the predefined effectiveness endpoint compared with unprotected TAVR controls. Illustration of the TriGuard HDH and performance measures (top right panels), the primary safety endpoint at 30 days (top left panel), and 3D rendering of topographical and size distribution and total new supra-threshold cerebral ischaemic lesion volume analysis across subjects by randomization group in the intention to treat (ITT) and in the full coverage per-treatment (PT) population.

1 September 2022 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
ZCZhaoyang Chen
Zhaoyang Chen
MMMitsuaki Matsumura
Mitsuaki Matsumura
GMGary S. Mintz
Gary S. Mintz
MNMasahiko Noguchi
Masahiko Noguchi
TFTatsuhiro Fujimura
Tatsuhiro Fujimura
AMAkiko Maehara
Akiko Maehara
Background: Clinical and morphological factors associated with lipidic versus calcified neoatherosclerosis within second-generation drug-eluting stents and the impact of lipidic versus calcified neoatherosclerosis on long-term outcomes after repeat intervention have not been well studied. Methods: A total of 512 patients undergoing optical coherence tomography before percutaneous coronary intervention for second-generation drug-eluting stents in-stent restenosis were included. Neoatherosclerosis was defined as lipidic or calcified neointimal hyperplasia in ≥3 consecutive frames or ruptured lipidic neointimal hyperplasia. The primary outcome was target lesion failure (cardiac death, target vessel myocardial infarction, definite stent thrombosis, or clinically driven target lesion revascularization). Results: The overall prevalence of neoatherosclerosis was 28.5% (146/512): 56.8% lipidic, 30.8% calcified, and 12.3% both lipidic and calcific. The prevalence increased as a function of time from stent implantation: 20% at 1 to 3 years, 30% at 3 to 7 years, and 75% >7 years. Renal insufficiency, poor lipid profile, and time from stent implantation were associated with lipidic neoatherosclerosis, whereas severe renal insufficiency, female sex, and time from stent implantation were associated with calcified neoatherosclerosis. Multivariable Cox regression revealed that female sex and lipidic neoatherosclerosis were associated with more target lesion failure, whereas stent age and final minimum lumen diameter after reintervention were related to lower target lesion failure. Calcified neoatherosclerosis was not related to adverse events after reintervention for in-stent restenosis given a large enough minimum lumen diameter was achieved. Conclusions: Lipidic but not calcified neoatherosclerosis was associated with poor subsequent outcomes after repeat revascularization if optimal stent expansion was achieved in lesions with calcified neoatherosclerosis.

4 May 2021 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
ZAZiad Ali
Ziad Ali
JHJennifer Horst
Jennifer Horst
PGPrakriti Gaba
Prakriti Gaba
LSLeslee J. Shaw
Leslee J. Shaw
SBSripal Bangalore
Sripal Bangalore
GSGregg W. Stone
Gregg W. Stone
Guideline‐based medical therapy is the foundation of treatment for individuals with coronary artery disease. However, revascularization with either percutaneous coronary intervention or coronary artery bypass grafting may be beneficial in patients with acute coronary syndromes, refractory symptoms, or in other specific scenarios (eg, left main disease and heart failure). While the goal of percutaneous coronary intervention and coronary artery bypass grafting is to achieve complete revascularization, anatomical and ischemic definitions of complete revascularization and their methodology for assessment remain highly variable. Such lack of consensus invariably contributes to the absence of standardized approaches for invasive treatment of coronary artery disease. Herein, we propose a novel, comprehensive, yet pragmatic algorithm with both anatomical and ischemic parameters that aims to provide a systematic method to assess complete revascularization after percutaneous coronary intervention or coronary artery bypass grafting in both clinical practice and clinical trials.

1 January 2021 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Open access
PDF file
JMJames M. McCabe
James M. McCabe
AKAmir A. Kaki
Amir A. Kaki
DPDuane S. Pinto
Duane S. Pinto
AKAjay J. Kirtane
Ajay J. Kirtane
WNWilliam J. Nicholson
William J. Nicholson
RTRaj Tayal
Raj Tayal
Background: There has been increasing utilization of short-term mechanical circulatory support devices for a variety of clinical indications. Many patients have suboptimal iliofemoral access options or reasons why early mobilization is desirable. Axillary artery access is an option for these patients, but little is known about the utility of this approach to facilitate short-term use for circulatory support with microaxial pump devices. Methods: The Axillary Access Registry to Monitor Safety (ARMS) was a prospective, observational multicenter registry to study the feasibility and acute safety of mechanical circulatory support via percutaneous upper-extremity access. Results: One hundred and two patients were collected from 10 participating centers. Successful device implantation was 98% (100 of 102). Devices were implanted for a median of 2 days (interquartile range, 0–5 days; range, 0–35 days). Procedural complications included 10 bleeding events and 1 stroke. There were 3 patients with brachial plexus–related symptoms all consisting of C8 tingling and all arising after multiple days of support. Postprocedural access site hematoma or bleeding was noted in 9 patients. Device explantation utilized closure devices alone in 61%, stent grafts in 17%, balloon tamponade facilitated closure in 15%, and planned surgical explant in 5%. Duration of support appeared to be independently associated with a 1.1% increased odds of vascular complication per day ([95% CI, 0.0%–2.3%] P =0.05). Conclusions: Percutaneous axillary access for use with microaxial support pumps appears feasible with acceptable rates of bleeding despite early experience. Larger studies are necessary to confirm the pilot data presented here.